Peptide deformylase as an antibacterial target: a critical assessment

Current Opinion in Pharmacology

Volumn 6, Issue 5, 2006, Pages 445-452

  Leeds, Jennifer A ^a   Dean, Charles R ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINONIN; AMINO ACID TRANSFER RNA LIGASE; ANTIINFECTIVE AGENT; INITIATION FACTOR 2; METHIONINE TRANSFER RNA; METHIONINE TRANSFER RNA LIGASE; METHIONYL AMINOPEPTIDASE; N (1 TERT BUTYL 2 DIMETHYLAMINO 2 OXOETHYL) 2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANAMIDE; N (5 FLUORO 1 OXIDO 2 PYRIDINYL) 1 [2 (N FORMYL N HYDROXYAMINOMETHYL)HEXANOYL]PROLINAMIDE; PEPTIDE DEFORMYLASE; PEPTIDE DEFORMYLASE INHIBITOR; TOLC PROTEIN;

AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTINEOPLASTIC ACTIVITY; BACTERIAL GENETICS; CANCER INHIBITION; DRUG DESIGN; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; ESCHERICHIA COLI; HUMAN; IC 50; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; PSEUDOMONAS AERUGINOSA; REVIEW; SEQUENCE HOMOLOGY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE;

AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIA; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; MOLECULAR SEQUENCE DATA;

EID: 33748430340     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.06.003     Document Type: Review

References (60)

1. Giglione C., Pierre M., and Meinnel T. Peptide deformylase as a target for new generation, broad spectrum antimicrobial agents. Mol Microbiol 36 (2000) 1197-1205
2. Miesel L., Greene J., and Black T.A. Genetic strategies for antibacterial drug discovery. Nat Rev Genet 4 (2003) 442-456
3. Ragusa S., Blanquet S., and Meinnel T. Control of peptide deformylase activity by metal cations. J Mol Biol 280 (1998) 515-523
4. Lazennec C., and Meinnel T. Formate dehydrogenase-coupled spectrophotometric assay of peptide deformylase. Anal Biochem 244 (1997) 180-182
5. Chen D.Z., Patel D.V., Hackbarth C.J., Wang W., Dreyer G., Young D.C., Margolis P.S., Wu C., Ni Z.J., Trias J., et al. Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry 39 (2000) 1256-1262
6. Jain R., Chen D., White R.J., Patel D.V., and Yuan Z. Bacterial peptide deformylase inhibitors: a new class of antibacterial agents. Curr Med Chem 12 (2005) 1607-1621. A thorough review of the chemistry of PDF inhibitors.
7. Ramanathan-Girish S., McColm J., Clements J.M., Taupin P., Barrowcliffe S., Hevizi J., Safrin S., Moore C., Patou G., Moser H., et al. Pharmacokinetics in animals and humans of a first-in-class peptide deformylase inhibitor. Antimicrob Agents Chemother 48 (2004) 4835-4842
8. Chen D., and Yuan Z. Therapeutic potential of peptide deformylase inhibitors. Expert Opin Investig Drugs 14 (2005) 1107-1116. This review provides a complete summary of the in vitro and in vivo data for the two PDF inhibitors that have progressed to human clinical trials.
9. Fritsche T.R., Sader H.S., Cleeland R., and Jones R.N. Comparative antimicrobial characterization of LBM415 (NVP PDF-713) a new peptide deformylase inhibitor of clinical importance. Antimicrob Agents Chemother 49 (2005) 1468-1476
10. Marcker K., and Sanger F. N-formyl-methionyl-S-RNA. J Mol Biol 12 (1964) 835-840
11. Schwartz J.H., Meyer R., Eisenstadt J.M., and Brawerman G. Involvement of N-formylmethionine in initiation of protein synthesis in cell-free extracts of Euglena gracilis. J Mol Biol 25 (1967) 571-574
12. Bianchetti R., Lucchini G., Crosti P., and Tortora P. Dependence of mitochondrial protein synthesis initiation on formylation of the initiator methionyl-tRNAf. J Biol Chem 252 (1977) 2519-2523
13. Adams J.M. On the release of the formyl group from nascent protein. J Mol Biol 33 (1968) 571-589
14. Meinnel T., and Blanquet S. Evidence that peptide deformylase and methionyl-tRNA(fMet) formyltransferase are encoded within the same operon in Escherichia coli. J Bacteriol 175 (1993) 7737-7740
15. Palma M., Worgall S., and Quadri L.E. Transcriptome analysis of the Pseudomonas aeruginosa response to iron. Arch Microbiol 180 (2003) 374-379
16. Thongboonkerd V., Luengpailin J., Cao J., Pierce W.M., Cai J., Klein J.B., and Doyle R.J. Fluoride exposure attenuates expression of Streptococcus pyogenes virulence factors. J Biol Chem 277 (2002) 16599-16605
17. Mazel D., Pochet S., and Marliere P. Genetic characterization of polypeptide deformylase, a distinctive enzyme of eubacterial translation. EMBO J 13 (1994) 914-923
18. Guilloteau J.P., Mathieu M., Giglione C., Blanc V., Dupuy A., Chevrier M., Gil P., Famechon A., Meinnel T., and Mikol V. The crystal structures of four peptide deformylases bound to the antibiotic actinonin reveal two distinct types: a platform for the structure-based design of antibacterial agents. J Mol Biol 320 (2002) 951-962
19. Smith K.J., Petit C.M., Aubart K., Smyth M., McManus E., Jones J., Fosberry A., Lewis C., Lonetto M., and Christensen S.B. Structural variation and inhibitor binding in polypeptide deformylase from four different bacterial species. Protein Sci 12 (2003) 349-360
20. Giglione C., Boularot A., and Meinnel T. Protein N-terminal methionine excision. Cell Mol Life Sci 61 (2004) 1455-1474
21. Zhou Z., Song X., and Gong W. Novel conformational states of peptide deformylase from pathogenic bacterium Leptospira interrogans: implications for population shift. J Biol Chem 280 (2005) 42391-42396
22. Fieulaine S., Juillan-Binard C., Serero A., Dardel F., Giglione C., Meinnel T., and Ferrer J.L. The crystal structure of mitochondrial (Type 1A) peptide deformylase provides clear guidelines for the design of inhibitors specific for the bacterial forms. J Biol Chem 280 (2005) 42315-42324
23. Guillon J.M., Heiss S., Soutourina J., Mechulam Y., Laalami S., Grunberg-Manago M., and Blanquet S. Interplay of methionine tRNAs with translation elongation factor Tu and translation initiation factor 2 in Escherichia coli. J Biol Chem 271 (1996) 22321-22325
24. Steiner-Mosonyi M., Creuzenet C., Keates R.A., Strub B.R., and Mangroo D. The Pseudomonas aeruginosa initiation factor IF-2 is responsible for formylation-independent protein initiation in P. aeruginosa. J Biol Chem 279 (2004) 52262-52269
25. Solbiati J., Chapman-Smith A., Miller J.L., Miller C.G., and Cronan Jr. J.E. Processing of the N termini of nascent polypeptide chains requires deformylation prior to methionine removal. J Mol Biol 290 (1999) 607-614
26. Miller C.G., Kukral A.M., Miller J.L., and Movva N.R. pepM is an essential gene in Salmonella typhimurium. J Bacteriol 171 (1989) 5215-5217
27. Brannigan J.A., Dodson G., Duggleby H.J., Moody P.C., Smith J.L., Tomchick D.R., and Murzin A.G. A protein catalytic framework with an N-terminal nucleophile is capable of self-activation. Nature 378 (1995) 416-419
28. Arfin S.M., and Bradshaw R.A. Cotranslational processing and protein turnover in eukaryotic cells. Biochemistry 27 (1988) 7979-7984
29. Wang W., White R., and Yuan Z. Proteomic study of peptide deformylase inhibition in Streptococcus pneumoniae and Staphylococcus aureus. Antimicrob Agents Chemother 50 (2006) 1656-1663. This work clearly demonstrates the distinct patterns of PDF inhibitor-dependent protein expression changes in two important human pathogens.
30. Bandow J.E., Becher D., Buttner K., Hochgrafe F., Freiberg C., Brotz H., and Hecker M. The role of peptide deformylase in protein biosynthesis: a proteomic study. Proteomics 3 (2003) 299-306
31. Apfel C.M., Locher H., Evers S., Takacs B., Hubschwerlen C., Pirson W., Page M.G., and Keck W. Peptide deformylase as an antibacterial drug target: target validation and resistance development. Antimicrob Agents Chemother 45 (2001) 1058-1064
32. Huntington K.M., Yi T., Wei Y., and Pei D. Synthesis and antibacterial activity of peptide deformylase inhibitors. Biochemistry 39 (2000) 4543-4551
33. Chambers H.F. Bactericidal vs. bacteriostatic antibiotic therapy: a clinical mini-review. Clinical Updates in Infectious Diseases 6 (2003) 1-6
34. Finberg R.W., Moellering R.C., Tally F.P., Craig W.A., Pankey G.A., Dellinger E.P., West M.A., Joshi M., Linden P.K., Rolston K.V., et al. The importance of bactericidal drugs: future directions in infectious disease. Clin Infect Dis 39 (2004) 1314-1320
35. Giglione C., Serero A., Pierre M., Boisson B., and Meinnel T. Identification of eukaryotic peptide deformylases reveals universality of N-terminal protein processing mechanisms. EMBO J 19 (2000) 5916-5929
36. Serero A., Giglione C., Sardini A., Martinez-Sanz J., and Meinnel T. An unusual peptide deformylase features in the human mitochondrial N-terminal methionine excision pathway. J Biol Chem 278 (2003) 52953-52963
37. Lee M.D., Antczak C., Li Y., Sirotnak F.M., Bornmann W.G., and Scheinberg D.A. A new human peptide deformylase inhibitable by actinonin. Biochem Biophys Res Commun 312 (2003) 309-315
38. Nguyen K.T., Hu X., Colton C., Chakrabarti R., Zhu M.X., and Pei D. Characterization of a human peptide deformylase: implications for antibacterial drug design. Biochemistry 42 (2003) 9952-9958
39. Lee M.D., She Y., Soskis M.J., Borella C.P., Gardner J.R., Hayes P.A., Dy B.M., Heaney M.L., Philips M.R., Bornmann W.G., et al. Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics. J Clin Invest 114 (2004) 1107-1116
40. Bracchi-Ricard V., Nguyen K.T., Zhou Y., Rajagopalan P.T., Chakrabarti D., and Pei D. Characterization of an eukaryotic peptide deformylase from Plasmodium falciparum. Arch Biochem Biophys 396 (2001) 162-170
41. Hou C, Conn HM, Brightwell R, Dirk LMA, Williams MA: Engineered tolerance to peptide deformylase inhibitors in Nicotiana tabacum. Plant Biology 2004. Lake Buena Vista, FL, July 2004. [Abstract #36]
42. Braun H.P., and Schmitz U.K. Purification and sequencing of cytochrome b from potato reveals methionine cleavage of a mitochondrially encoded protein. FEBS Lett 316 (1993) 128-132
43. Houtz RL, Dirk LMA, Williams MA: Inhibitors of plant peptide deformylase for use as broad-spectrum herbicides and method for identifying the same. US Patent # 6,730,634.
44. Margolis P.S., Hackbarth C.J., Young D.C., Wang W., Chen D., Yuan Z., White R., and Trias J. Peptide deformylase in Staphylococcus aureus: resistance to inhibition is mediated by mutations in the formyltransferase gene. Antimicrob Agents Chemother 44 (2000) 1825-1831
45. Clements J.M., Beckett R.P., Brown A., Catlin G., Lobell M., Palan S., Thomas W., Whittaker M., Wood S., Salama S., et al. Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Antimicrob Agents Chemother 45 (2001) 563-570
46. Nilsson A.I., Zorzet A., Kanth A., Dahlstrom S., Berg O.G., and Andersson D.I. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc Natl Acad Sci USA 103 (2006) 6976-6981. This work describes the selection of intergenic and intragenic suppressors of fitness defects associated with PDF bypass mutants that are resistant to actinonin. This discovery suggests that the fitness cost associated with bypass of PDF could be overcome in an infected patient.
47. Leeds JA, Dean CR, Favre B, Narayan S, Sachdeva M, Medeiros J, Dzink-Fox J, Ryder NS: In vitro selection of decreased susceptibility to the novel peptide deformylase inhibitor LBM415 in three pathogens. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004. [Abstract #C1-1880]
48. Margolis P, Hackbarth C, Maniar M, Lopez S, White R, Yuan Z, Trias J: Distinct mechanisms of resistance to deformylase inhibitors in Haemophilus influenzae and Streptococcus pneumoniae. 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000.
49. Newton D.T., Creuzenet C., and Mangroo D. Formylation is not essential for initiation of protein synthesis in all eubacteria. J Biol Chem 274 (1999) 22143-22146
50. Guillon J.M., Mechulam Y., Schmitter J.M., Blanquet S., and Fayat G. Disruption of the gene for Met-tRNA(fMet) formyltransferase severely impairs growth of Escherichia coli. J Bacteriol 174 (1992) 4294-4301
51. Bjorkman J., Nagaev I., Berg O.G., Hughes D., and Andersson D.I. Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance. Science 287 (2000) 1479-1482
52. Watters A.A., Jones R.N., Leeds J.A., Denys G., Sader H.S., and Fritsche T.R. Antimicrobial activity of a novel peptide deformylase inhibitor, LBM415, tested against respiratory tract and cutaneous infection pathogens: a global surveillance report (2003-2004). J Antimicrob Chemother 57 (2006) 914-923. This report describes the identification of a PDF inhibitor-resistant clinical isolate of S. aureus during routine surveillance. This discovery demonstrates pre-existing PDF inhibitor resistance in patients before use of PDF inhibitors in the clinic.
53. Balakrishnan A., Patel B., Sieber S.A., Chen D., Pachikara N., Zhong G., Cravatt B.F., and Fan H. Metalloprotease inhibitors GM6001 and TAPI-0 inhibit the obligate intracellular human pathogen Chlamydia trachomatis by targeting peptide deformylase of the bacterium. J Biol Chem (2006)
54. Dean CR, Narayan S, Richards J, Leeds J, Esterow S, Kamp H, Puyang X, Wiedmann B, Muller D, Voshol J, Van Oostrum Y, Dzink-Fox J, Ryder NS: Overexpression of peptide deformylase decreases susceptibility to the peptide deformylase inhibitor LBM415 in Haemophilus influenzae. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2005. [Abstract #C1-1461.]
55. Kumar A., and Schweizer H.P. Bacterial resistance to antibiotics: active efflux and reduced uptake. Adv Drug Deliv Rev 57 (2005) 1486-1513
56. Sanchez L., Pan W., Vinas M., and Nikaido H. The acrAB homolog of Haemophilus influenzae codes for a functional multidrug efflux pump. J Bacteriol 179 (1997) 6855-6857
57. Dean C.R., Narayan S., Daigle D.M., Dzink-Fox J.L., Puyang X., Bracken K.R., Dean K.E., Weidmann B., Yuan Z., Jain R., et al. Role of the AcrAB-TolC efflux pump in determining susceptibility of Haemophilus influenzae to the novel peptide deformylase inhibitor LBM415. Antimicrob Agents Chemother 49 (2005) 3129-3135
58. Neckermann G, Dean CR, Yu D, Manni KL, Narayan S, Dzink-Fox J: Role of AcrAB-TolC efflux in reducing susceptibility to LBM415 and macrolides in a Haemophilus influenzae murine lung infection model. 45th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, New Orleans, LA, 2005.
59. Robien M.A., Nguyen K.T., Kumar A., Hirsh I., Turley S., Pei D., and Hol W.G. An improved crystal form of Plasmodium falciparum peptide deformylase. Protein Sci 13 (2004) 1155-1163
60. Waites K.B., Reddy N.B., Crabb D.M., and Duffy L.B. Comparative in vitro activities of investigational peptide deformylase inhibitor N LBM-415 and other agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother 49 (2005) 2541-2542